Bermuda, Testimonials and Cell-Free Therapy: How Offshore Structures Can Put Accountability Out of Reach

When a medical-facing company promotes expensive regenerative treatments, publishes patient success stories, and operates across multiple countries, one question becomes unavoidable:

Who is actually accountable?

That question sits at the heart of Wellbeing International Foundation’s public-facing structure. The organisation promotes Cell-Free Therapy, presents testimonials from athletes and patients, and lists its corporate address in Bermuda. On its main website, Wellbeing describes Cell-Free Therapy as a preparation involving growth factors from a blood draw, processed in a GMP-certified laboratory. On its separate testimonial website, it presents stories from individuals who say they experienced improvements after treatment.

The Bermuda address is not, by itself, evidence of wrongdoing. Many legitimate companies operate from offshore financial centres. But when offshore corporate structures are combined with high-value medical treatments, emotional patient testimonials, cross-border laboratory processing, and implied health outcomes, the public-interest question becomes sharper.

Where does responsibility sit?

With the Bermuda company?

With the German laboratory?

With the partner clinic?

With the person selling the treatment?

With the doctor who administers it?

Or with nobody clearly visible to the patient at all?

The Offshore Problem

Offshore jurisdictions such as Bermuda, Panama, the British Virgin Islands and the Cayman Islands are often promoted as efficient, tax-neutral, internationally recognised business centres. That is the official version.

The more uncomfortable reality is that offshore structures can also make ownership, control, liability, and money flows harder to see.

Transparency International has repeatedly warned that opaque ownership structures can be abused to conceal who ultimately owns, controls or benefits from a company. The issue is not simply where a company is registered. The issue is whether the real people behind the operation can be identified and held accountable.

This matters deeply in medicine.

A patient buying a treatment is not buying a T-shirt or a software subscription. They are placing trust in a medical claim, a scientific claim, and often a human promise. If the outcome is poor, misleading, or harmful, the patient needs to know who was responsible.

Offshore structures can make that path more difficult.

Wellbeing’s Bermuda Footprint

Wellbeing International Foundation’s testimonial website lists the address:

Williams House20 Reid StreetHamilton HM11Bermuda

The same testimonial website uses the contact email:

info@wellbeingint.com

This connects the testimonial platform directly to the wider Wellbeing International Foundation brand.

That matters because the testimonial website is not an independent review platform. It is not Trustpilot. It is not a regulator. It is not a medical registry. It is a company-controlled marketing asset.

Its purpose is to present favourable stories.

That does not mean the testimonials are false. But it does mean they are promotional material, not independent evidence.

Testimonials Are Not Clinical Proof

The testimonial site presents stories involving athletes, injury recovery, pain, performance, long-term health and chronic conditions. Some testimonials describe improvements after infusions. Others imply benefits in complex medical situations.

This is where the marketing becomes sensitive.

A testimonial can be emotionally powerful and still scientifically weak.

A patient may sincerely believe a treatment helped them. An athlete may genuinely feel they recovered faster. But without controlled trials, independent medical records, objective before-and-after data, and proper follow-up, a testimonial remains anecdote.

In medicine, anecdotes are not proof.

Regulators understand this problem. The UK Advertising Standards Authority says testimonials used in marketing still count as advertising claims. If a testimonial makes or implies a factual claim, the advertiser must hold evidence to substantiate it.

That principle is critical.

A company cannot avoid responsibility for medical implications simply by putting them in the mouth of a happy patient.

The Disclaimer Versus the Story

Wellbeing’s main website includes cautious disclaimer language, stating that Cell-Free Therapy is not intended to diagnose, treat, cure, or prevent disease.

Yet the testimonial-driven marketing ecosystem points visitors toward stories of recovery, stabilisation, healing, performance and improved wellbeing.

This creates a familiar pattern in alternative and regenerative medicine marketing:

The formal disclaimer says one thing.

The testimonial says another.

The disclaimer protects the company.

The testimonial persuades the patient.

That contrast deserves scrutiny.

If a company says its product is not intended to treat disease, why publish stories that appear to connect the product with disease-related outcomes?

If the product is merely supportive of normal biological function, why use testimonials that imply recovery from injury, chronic symptoms, or neurological decline?

These are fair questions.

Why a Separate Testimonial Website?

The existence of a separate testimonial domain is itself revealing.

If testimonials already exist on the main website, why build a second website dedicated entirely to testimonials?

There are several likely reasons.

First, search visibility. A separate domain can help dominate online searches for the company’s name plus terms such as “reviews,” “testimonials,” “success stories,” and “results.”

Second, reputation management. When potential clients research a company, positive testimonial content can occupy more space in search results.

Third, sales support. A testimonial site becomes a convenient link for sales teams, representatives, partner clinics, and promoters to send to prospects.

Fourth, emotional conversion. A visitor landing on a dedicated testimonial site is surrounded by success stories, not balanced scientific debate.

This is marketing architecture.

Again, that is not automatically unlawful. But in the context of expensive medical-facing treatments, it becomes a legitimate investigative concern.

Offshore Structures and Shell Company Abuse

The Panama Papers showed the world how offshore companies can be used to hide wealth, ownership, and control. The International Consortium of Investigative Journalists exposed millions of documents showing how offshore structures were used by politicians, business figures, criminals and intermediaries around the world.

Panama was central to that scandal, but the broader issue was not Panama alone. It was the offshore model: companies, nominees, trusts, secrecy, distance, and complexity.

Bermuda has also faced scrutiny as part of the global debate over beneficial ownership transparency. Bermuda presents itself as a compliant and well-regulated jurisdiction, and it is important to acknowledge that. But transparency campaigners have continued to argue that offshore financial centres must provide stronger access to beneficial ownership information for journalists, civil society and investigators.

This is the key point:

A structure can be legal and still reduce visibility.

A company can be registered properly and still be difficult for the public to understand.

An offshore address can be legitimate and still raise questions when combined with cross-border medical marketing.

The Accountability Gap

For patients, the practical problem is simple.

If something goes wrong, who do they sue?

If a testimonial is misleading, who regulates it?

If a clinic administers the treatment in one country, a lab processes material in another, and the brand is headquartered in Bermuda, which authority takes responsibility?

This is where offshore medical marketing becomes especially concerning.

Regulators are usually national.

Marketing is digital.

Patients are international.

Money moves quickly.

Corporate responsibility may be spread across several entities.

This creates an accountability gap.

A patient in the United Kingdom, United States, Europe or the Middle East may encounter marketing from one entity, speak to a representative in another country, receive treatment through a partner clinic, and later discover that the brand itself is registered offshore.

That does not mean fraud has occurred.

But it does mean accountability becomes more difficult.

Why This Matters in Cell-Free Therapy

Cell-Free Therapy sits within the broader world of regenerative medicine, a field that has attracted both serious scientific interest and aggressive commercial exploitation.

The U.S. Food and Drug Administration has repeatedly warned consumers about regenerative medicine products, including stem cell and exosome-related products, being marketed for unapproved uses. Regulators have warned that patients may be exposed to products promoted for conditions where safety and efficacy have not been established.

This is why testimonial marketing is so powerful — and so dangerous.

Patients do not always ask for peer-reviewed evidence.

They ask, “Did it work for someone like me?”

That is exactly what testimonial websites are designed to answer.

But medicine cannot be built on emotional similarity.

It must be built on evidence.

The Questions Wellbeing Should Answer

Wellbeing International Foundation should be asked clear, direct questions:

Who are the beneficial owners of the Bermuda entity?

Why is the organisation headquartered in Bermuda?

Who receives payment from patients?

Which entity contracts with patients?

Which clinics administer the therapy?

Which doctors are responsible for patient assessment?

Which regulator oversees the marketing claims?

What clinical evidence supports the outcomes described in testimonials?

Were testimonials independently verified?

Were patients paid, discounted, or incentivised?

Were athletes paid or commercially connected?

Are adverse outcomes also recorded and published?

What happens if a patient is harmed?

These questions are not hostile.

They are basic accountability questions.

Any medical-facing organisation asking patients to trust it should be able to answer them.

Conclusion

The issue is not simply Bermuda.

The issue is visibility.

Wellbeing International Foundation’s use of a Bermuda address, combined with a separate testimonial website and broad Cell-Free Therapy marketing, raises legitimate questions about transparency, accountability and patient protection.

Offshore incorporation is not proof of misconduct.

Testimonials are not proof of treatment effectiveness.

Disclaimers are not a substitute for evidence.

And patient hope should never be used as a shield against scrutiny.

In medicine, the burden should always rest with the promoter of the treatment.

Show the evidence.

Show the ownership.

Show the regulator.

Show the contracts.

Show who is accountable.

Because when medical marketing crosses borders, patients deserve more than stories.

They deserve answers.